In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice

Gene Therapy

Volumn 5, Issue 3, 1998, Pages 388-393

  Sacco, M G ^a   Barbieri, O ^b   Piccini, D ^b   Noviello, E ^b   Zoppe M ^a   Zucchi, I ^a   Frattini, A ^a   Villa, A ^a   Vezzoni, P ^a  

^a CNR   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antisense therapy; Liposome; Mammary adenocarcinoma; MMTV neu; Transgenic mice

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CLONING VECTOR; CONTROLLED STUDY; FEMALE; GENE THERAPY; IMMUNOBLOTTING; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS MUSCULUS;

EID: 0031908626     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300592     Document Type: Article

References (19)

1. Hanahan D Transgenic mice as probes into complex systems. Science 1989; 246: 1265-1275.
2. Pattengale PK et al. Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am J Pathol 1989; 135: 39-61.
3. Jacks T. Tumor suppressor gene mutations in mice. Annu Rev Genet 1996; 30: 603-636.
4. Sacco MG et al. Local regression of breast tumors following intramammary ganciclov̈ir administration in double transgenic mice expressing neu oncogene and herpes symplex virus thyrmidine kinase. Gene Therapy 1995; 2: 493-497.
5. Sacco MG et al. Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer in vivo. Gene Therapy 1996; 3: 1151-1156.
6. Lucchini F et al. Early and multifocal tumors in breast, salivary, harderian and epididimal tissues developed in MMTV-Neu transgenic mice. Cancer Lett 1992; 64: 203-209.
7. Hynes NE, Stern DF. The biology of erbB-2neu/HER-2 and its role in cancer. Biochem Biophys Acta 1994; 1198: 165-184.
8. Dougall WC et al. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994; 9: 2109-2123.
9. Sacco MG et al. Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Res Treat (in press).
10. Muller WJ, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105-115.
11. Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J Biol Chem 1996; 271: 7673-7678.
12. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1993; 32: 329-376.
13. Indolfi C Chiariello M, Avvedimento EV. Selective gene therapy for proliferative disorders: sense and antisense. Nature Med 1996; 2: 634-635.
14. Monia BP et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 1996, 2: 668-675.
15. Ledda MF et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Med 1997; 3: 171-176
16. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor receptor-1 in human melanomas blocks intrarumoral angiogenesis and tumor growth. Nature Med 1997; 3: 887-893.
17. Vaughn JP et al. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 1995; 92: 8338-8342.
18. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989